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Protein nitrationcardiotoxicity is thought to be mediated by the generation of superoxide anion
radicals (superoxide) from redox cycling of DOX in cardiomyocyte mitochondria. Reduction of superoxide
generates H2O2, which diffuses throughout the cell and potentially contributes to oxidant-mediated cardiac
injury. The mitochondrial and cytosolic glutathione peroxidase 1 (Gpx1) primarily functions to eradicate
H2O2. In this study, we hypothesize that Gpx1 plays a pivotal role in the clearance of H2O2 generated by
DOX. To test this hypothesis, we compared DOX-induced cardiac dysfunction, mitochondrial injury, protein
nitration, and apoptosis in Gpx1-deﬁcient and wild type mouse hearts. The Gpx1-deﬁcient hearts
showed increased susceptibility to DOX-induced acute functional derangements than wild type hearts,
including impaired contractility and diastolic properties, decreased coronary ﬂow rate, and reduced heart
rate. In addition, DOX treatment impaired the mitochondrial function of Gpx1-deﬁcient hearts. Speciﬁcally,
Gpx1-deﬁcient hearts treated with DOX demonstrated an increased rate of NAD-linked state 4 respiration
and a decline in the P/O ratio relative to wild type hearts, suggesting that DOX uncouples the electron
transfer chain and oxidative phosphorylation in Gpx1-deﬁcient hearts. Finally, apoptosis and protein
nitration were signiﬁcantly increased in Gpx1-deﬁcient mouse hearts compared to wild type hearts. These
studies suggest that Gpx1 plays signiﬁcant roles in protecting DOX-induced mitochondrial impairment and
cardiac dysfunction in the acute phase.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Doxorubicin (DOX) is an anthracycline antibiotic that is widely used
as a chemotherapeutic agent. However, the administration of DOX is
known to induce numerous cardiotoxic effects, including transient
arrhythmias, nonspeciﬁc electrocardiographic abnormalities, pericardi-
tis, and acute heart failure [1,2]. DOX can also cause congestive heart
failuremonthsor years after treatment. ThemechanismofDOX-induced
cardiac injury has been actively investigated, and several hypotheses
have been suggested to explain the acute and chronic cardiotoxicity of
DOX. These include the formation of free radicals, inhibition of enzymes
and proteins, changes in cardiac muscle gene expression, alterations of
mitochondrial membrane function, sensitization of Ca2+ release from
sarcoplasmic reticulum channels, mitochondrial DNA damage and
dysfunction [3], and induction of apoptosis [4,5].
The free radical hypothesis of DOX-induced cardiotoxicity has
gained signiﬁcant support [6,7]. DOX is known to generate free radicalsl rights reserved.either by redox cycling between a semi-quinone form and a quinone
form or through the formation of a DOX–Fe3+ complex [8]. Molecular
oxygen is reduced to superoxide anion (O2−), which is converted to
other forms of reactive oxygen species such as hydrogen peroxide
(H2O2) and hydroxyl radical (OH·). It is hypothesized that free radicals
induce damage to the heart, an organ that is known to have a relatively
low level of antioxidant enzymes such as superoxide dismutase (SOD)
and catalase [9]. In support of this hypothesis, DOX-induced cardio-
toxicity can be inhibited by the overexpression of antioxidant enzymes
MnSOD and catalase [10,11].
MnSOD, which is located in mitochondria, speciﬁcally reduces
superoxide to H2O2. In turn, H2O2 is decomposed by the enzymes
catalase, glutathione peroxidase, and peroxiredoxin in mammalian
cells [12,13]. Catalase is located in the peroxisomes of cells [14],
so diffusion of H2O2 from other subcellular sites is necessary. The
major isoform of glutathione peroxidase, glutathione peroxidase 1
(Gpx1), is present in both mitochondria and the cytosol [15]. The
location and low Km of Gpx1 for H2O2 may facilitate its ability to
detoxify the H2O2 that is generated in the mitochondria of the
heart following DOX treatment [16,17]. It has been shown that an
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contribute to DOX-induced cardiotoxicity [18,19]. Treatment with
probucol increases cardiac Gpx1 activity, decreases lipid peroxida-
tion, and improves mortality [18]. All of these lines of evidence
suggest that Gpx1 may play a role in minimizing the cardiotoxicity
of DOX.
If Gpx1 indeed does minimize DOX-induced cardiotoxicity, then it
follows that Gpx1 deﬁciency would render hearts more susceptible
to DOX-induced cardiotoxicity. To explore this hypothesis, cardiac
performance was measured in a DOX-treated isolated mouse heart
preparation as well as DOX-treated mouse hearts in vivo. In addition,
this study measured the mitochondrial function, amount of apoptosis,
and level of protein nitration in the hearts of DOX-treated Gpx1-
deﬁcient mice and their wild type littermates.
2. Materials and methods
2.1. Materials
DOX HCl (2 mg/ml) was purchased from Bedford Laboratories
(Bedford, OH). An ApopTag In Situ Oligo Ligation kit was obtained from
Chemicon International (Temecula, CA). All other reagents were of the
highest grades commercially available.
2.2. Animal studies
Gpx1 knockout mice (Gpx1−/−) were generated as described pre-
viously [20]. Gpx1 is the predominant form of the Gpx isozymes, and
little to no Gpx activity was detected in tissues of homozygous
knockout mice. In the heart, Gpx activity in knockout mice is less than
10% of the total Gpx activity in wild type mice [20]. Mice were main-
tained in AAALAC-accredited, climate-controlled facilities. Wild type
Gpx1+/+ and Gpx1−/− mice (4–5 months old, in a C57BL/6 and 129SV
mixed genetic background) were randomly assigned to four groups:
Gpx1+/+, Gpx1+/++DOX, Gpx1−/−, or Gpx1−/−+DOX. A single dose of
DOX (22.5 mg/kg, i.p.) or an equivalent volume of saline was injected.
These animals were free of pathogens during the entire course of
experiments. All the animal protocols were approved by the East
Tennessee State University Animal Committee.
2.3. Isolation of cardiac mitochondria and measurement of
mitochondrial respiratory and phosphorylating activities
Mouse cardiac mitochondria were isolated, and their respiratory
and phosphorylating activities measured according to the methods
described previously [21]. Respiratory control index (RCI) is deﬁned as
the ratio of the state 3 respiratory rate to the state 4 respiratory rate.
ADP/O ratio (P/O ratio) was determined by dividing the amount
(nmol) of ADP added by the amount (natoms=nanoatoms) of oxygen
consumed during state 3 respiration [22].
2.4. In vitro cardiac function measurement
In vitro mouse cardiac function was analyzed in a modiﬁed
Langendorff perfusion model as previously described [23]. Brieﬂy,
age- and gender-matched Gpx1+/+ and Gpx1−/− mice were injected
with anticoagulant sodium heparin (500 U/kg, i.p.) 20 min prior to
anesthetizationwith sodiumpentobarbital (120mg/kg, i.p.). Following
anesthetization, mouse hearts were rapidly removed, cannulated, and
perfused retrogradely at 37 °C with a Krebs–Henseleit bicarbonate
buffer. After 30 min perfusion to stabilize the cardiac function, mouse
heartswere perfusedwith the buffer in the presence or absence of DOX
for another 60 min. The left ventricular pressure trace was continu-
ously recorded through a pressure transducer connected to a com-
puterized data acquisition system (DATAQ Instruments, Inc., Akron,
OH). The coronary efﬂuent was collected and measured every 15 min.Cardiac function parameters, including heart rate (HR), left ventricular
developed pressure (LVDP), and maximum development of pressure
over time (±dP/dt), were analyzed from the recorded data with a
software.
2.5. Analysis of in vivo cardiac function
A single dose of DOX (22.5 mg/kg, i.p.) or an equivalent volume of
saline was injected. Five days after DOX or saline administration, mice
were injected with heparin (500 U/kg, i.p.) and anesthetized with 2%
isoﬂurane. Each mouse was intubated with a 22-gauge soft catheter
and ventilated with a rodent ventilator (Columbus Instruments
International Corp., Columbus, OH) at a tidal volume of 0.3–0.5 ml
and a respiratory rate of 120 breaths/min. After left thoracotomy, the
pericardium was dissected to expose the heart. A microtip pressure–
volume catheter (SPR-839; Millar Instruments, Houston, TX) was
inserted through a 25-gauge apical stab into the left ventricle to
measure steady state cardiac function. To change the cardiac preload,
the inferior vena cava was occluded for 1 s. At the completion of the
study,10 µl of hypertonic saline (15%)was injected into the right atrium
to calibrate Vp, the parallel volume. The signals were continuously
recorded at a sampling rate of 1000 s−1 using anARIApressure–volume
conductance system (Millar Instruments) coupled to a Powerlab/4SP
A/D converter (AD Instruments, Mountain View, CA). All pressure–
volume loop data were analyzed with a cardiac pressure–volume
analysis program (PVAN3.4; Millar Instruments). At the end of
function analysis, animals were anesthetized with tribromoethanol
(270 mg/kg, i.p.). Hearts were removed and perfused for 2 min as
Langendorff preparations to remove the remaining blood. Portions
of the mid-ventricle were ﬁxed in 4% buffered formaldehyde for
24 h, dehydrated, and embedded for immunological and apoptosis
studies.
2.6. ISOL analysis
A 2-mm section of mid-ventricles was sliced, ﬁxed in 4% buffered
formaldehyde for 24 h, dehydrated, and embedded. Myocardial
sections (5 µm) were mounted on siliconized slides and dried at
37 °C overnight. In situ staining of DNA strand breaks in the serial
section of each specimen was detected by the ApopTag ISOL (In Situ
Oligo Ligation) kit using oligo A as previously described [24]. The
percentage of ISOL-positive myocytes was determined by counting 10
random ﬁelds per section under an Olympus BX40 microscope.
2.7. Immunohistochemistry
Immunostaining of nitrotyrosine in mouse hearts was performed
using monoclonal anti-nitrotyrosine antibody at a dilution of 1:200
(Cayman, Ann Arbor, MI) at 4 °overnight. Antigen–antibody complexes
were detected by the Super-sensitive alkaline phosphatase kit
(BioGenex; San Ramon, CA) using fast red as a chromogen. Hematox-
ylin was used as a counterstain. Images were captured using a SPOT
camera and transferred into research-based digital image analysis
software (Image Pro Plus; Media Cybernetics, Silver Spring, MD). The
extent of immunoreactivity in the LV was determined in the tissues by
applying intensity thresholding analysis [25]. The sum density of total
LV image pixels in the 80-to-155 rangewas used as a semi-quantitative
measure of relative immunoreactivity.
2.8. Statistical analysis
All values were expressed as mean±SEM. One-way ANOVA was
used followed by Tukey's multiple comparison tests if there were
signiﬁcant differences between groups. Signiﬁcance of differences
between two groups was established by Student's t-test. Signiﬁcance
was indicated if Pb0.05.
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3.1. Mouse hearts deﬁcient in Gpx1 are more susceptible to DOX-induced
cardiac dysfunction
In vitro cardiac function was analyzed in a mouse heart perfusion
model to determine the role of Gpx1 in protecting hearts against DOX-
induced cardiotoxicity. Our study found that DOX caused signiﬁcantly
more cardiac dysfunction in Gpx1-deﬁcient (Gpx1−/−) mouse hearts
than in wild type or Gpx−/− mice. However, as shown in Table 1, there
was no difference in the basal levels of hemodynamic indices of
cardiac function between the wild type mice and Gpx1−/− mice;
however, perfusion with 5 µM DOX for 60 min resulted in both
inotropic and chronotropic dysfunction. As shown in Fig. 1, hearts
from Gpx1−/− mice showed a 44% suppression of +dP/dt (maximum
rate of pressure development during systole), a 47% suppression of
−dP/dt (maximum rate of pressure development during diastole), and
a 34% suppression of LVDP (left ventricular developed pressure)
following exposure to DOX for 60 min, compared to a 14% suppression
of +dP/dt, a 12% suppression of −dP/dt, and a 10% reduction of LVDP
from Gpx1+/+ mice. The chronotropic index of cardiac function HR
decreased 9% in Gpx1+/+ hearts and 34% in Gpx1−/− mouse hearts
following exposure to DOX for 60min (Pb0.05 compared to that in the
Gpx1+/+ mice). With HR×LVDP, which measures both inotropic and
chronotropic changes, homozygous Gpx1−/− mouse hearts displayed a
49% reduction vs. a 14% reduction in Gpx1+/+ mice.
The above data indicate that DOX induces signiﬁcantly greater
cardiac dysfunction in Gpx1−/− mice. In addition, the coronary ﬂow
rate during DOX perfusion was reduced from 43% in Gpx1−/− to 13%
in the Gpx1+/+ mice, suggesting that the decrease of cardiac per-
fusion is either due to vascular constriction or endothelial damage
following exposure to DOX. Overall, the in vitro cardiac function
study suggests that knockout of the Gpx1 gene leads to signiﬁcantly
compromised cardiac systolic and diastolic function following expo-
sure to DOX.
To further validate our in vitro study ﬁndings, we investigated
cardiac function in DOX-treated Gpx1−/− mice and their wild type
littermates with a sophisticated in vivo functional study. As summar-
ized in Table 2, there was no difference between the initial body
weight and cardiac function of Gpx1+/+ mice and Gpx1−/− mice. DOX-
treated mice showed numerous changes after 5 days of treatment.
First, DOX treatment caused weight loss in both Gpx1−/− mice and
Gpx1+/+ mice, but the weight loss was signiﬁcantly greater in Gpx1−/−
mice. Second, DOX treatment led to profound suppression of systolic
cardiac function in both Gpx1−/− mice and Gpx1+/+ mice, but the
suppression was signiﬁcantly higher in Gpx1−/− mice. Indeed, ejection
fraction was signiﬁcantly lower in Gpx1−/− mice compared to Gpx1+/+
mice (41.8±1.71% vs. 51.2±1.01%, Pb0.05), which was the result of
a greater suppression of end-systolic ventricular pressure (60.5±
2.68 mmHg vs. 67.1±1.69 mmHg, Pb0.05) and a greater elevation ofTable 1
Basal levels of cardiac parameters of perfused mouse hearts
Gpx1+/+ Gpx1+/++DOX Gpx1−/− Gpx1−/−+DOX
HR (beats/min) 278±10 278±17 270±10 287±14
LVDP (mmHg) 75.3±4.5 82.4±2.2 80.4±1.5 76.8±2.3
+dP /dt (mmHg/s) 2882±271 2580±100 2527±208 2617±99
−dP /dt (mmHg/s) 1665±176 1612±72 1644±136 1773±93
HR×LVDP 22943±1377 23612±903 21769±1418 23471±587
CFR (ml/min) 1.38±0.10 1.28±0.05 1.29±0.07 1.27±0.09
Values represent the cardiac functional parameters before exposure to buffer only or
buffer containing DOX and are expressed as mean±SEM of six mouse hearts.
Measurements of the maximum rates of pressure development (±dP /dt), left
ventricular developed pressures (LVDP), heart rates (HR), and coronary ﬂow rate
(CFR) were made after 30 min of preliminary perfusion. There is no signiﬁcant
difference among all groups.end-systolic volume (9.19±0.18 μl vs. 7.83±0.26 μl, Pb0.05). The pres-
sure development rate of the left ventricle (+dP/dt) was signiﬁcantly
reduced in Gpx1−/− mice compared to the Gpx1+/+ group (4406±
331 mmHg/s vs. 5566±111 mmHg/s, Pb0.05), which in return
accounted for the greater suppression in preload recruitable stroke
work (PRSW) in Gpx1−/− mice (44.5±3.26 vs. 62.2±2.96 mm Hg).
Finally, Gpx1−/− mice showed signiﬁcantly worse diastolic function
following DOX treatment than Gpx1+/+ mice. The end-diastolic volume
was more reduced in Gpx1−/−mice compared to Gpx1+/+ mice (14.87±
0.50 μl vs. 16.02±0.25 μl, Pb0.05). LV diastolic dysfunction was also
more impaired in Gpx1−/− mice, as evidenced by the suppressed
maximal rate of LV pressure decreasing (5599±142mmHg/s vs. 3504±
336 mmHg/s, Pb0.05) and elevated time constant of isovolumic
relaxation (7.96±0.26 ms vs. 10.26±0.64 ms). It is worthwhile to
mention that although the slope of end-diastolic pressure–volume
relationship (β) is lower in both Gpx1−/− and Gpx1+/+ mice following
DOX treatment, we did not ﬁnd a signiﬁcant difference between the
DOX-treatedGpx1−/− and Gpx1+/+ and saline-treated controls. DOX had
a signiﬁcant effect on peripheral vascular resistance (Ea) in Gpx1−/−
mice, but not in Gpx1+/+ mice.
In summary, DOX treatment produced a profound impairment
on cardiac performance in both Gpx1−/− and Gpx1+/+ mice, but the
impairments were more pronounced in Gpx1−/− mice.
3.2. Mouse hearts deﬁcient in Gpx1 are more susceptible to DOX-induced
mitochondrial dysfunction
Mitochondria are the primary subcellular organelle in which
DOX-induced generation of ROS is observed. Therefore, mitochon-
dria are a direct target of oxidative stress. We measured the
efﬁciency of mitochondrial respiration in mouse hearts 1 day after
DOX administration to elucidate the biochemical abnormalities
that occur in cardiac mitochondria in response to DOX treatment.
We utilized NAD-linked substrates (glutamate and malate) in the
measurement of mitochondrial respiration. DOX treatment had
no effect on state 3 respiration in cardiac mitochondria of either
wild type or Gpx1−/− (Fig. 2A). However, DOX caused a 64% increase
in the rate of state 4 respiration in cardiac mitochondria of Gpx1−/−
mice as compared to saline-treated counterparts. However, this
was not observed in cardiac mitochondria of wild type mice
(Fig. 2B).
RCI is derived from the ratio of the rate of state 3 respiration to the
rate of state 4 respiration. Thus, a change in the state 4 respiratory rate
would lead to an altered RCI. RCI of cardiac mitochondria from Gpx1−/−
mice treated with DOX was 56% of the RCI of saline-treated mice
(Fig. 2C). Although the rates of state 3 and state 4 respiration in cardiac
mitochondria of wild type mice were statistically unaffected by DOX
treatment, a relatively modest decrease (26%) of RCI was observed in
these samples.
The decrease in RCI of Gpx1−/− mitochondria in response to DOX
treatment was greater than wild type mitochondria (pb0.001).
DOX treatment also decreased the P/O ratio in wild type or Gpx1−/−
mice. The P/O ratio of the latter samples was lower than the former
(pb0.001) (Fig. 2D).
The effect of DOX on mitochondrial respiration with FAD-
linked substrate (succinate) was not as dramatic as the effect with
NAD-linked substrates. DOX treatment did not alter the rates
of state 3 and state 4 respiration and RCI in wild type and Gpx1−/−
mice (Fig. 3A–C). The P/O ratio of Gpx1−/− cardiac mitochondria,
but not wild type mitochondria, was decreased by 20%, as
compared to mitochondria isolated from saline-treated counter-
parts (Fig. 3D).
These studies demonstrate that DOX treatment impairs mitochon-
drial respiration in hearts of wild type and Gpx1−/−mice. However, the
extent of functional decline in cardiac mitochondria of Gpx1 knockout
mice is signiﬁcantly increased.
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Apoptosis is observed in cultured cardiomyocytes and hearts of
DOX-treated animals [4,5]. The ISOL method, which is more speciﬁc
for double-stranded DNA breaks during apoptosis, was used to
identify apoptotic myocytes in DOX-treated mouse hearts. The results
showed that 9±0.8% of cardiomyocytes in DOX-treated Gpx1+/+ miceFig. 1. Effect of DOX on the cardiac function and coronary ﬂow rate of hearts from Gpx1−/− a
described in Materials and methods. Cardiac function parameters are expressed as the recove
the ﬁrst 30-min perfusion. Open and ﬁlled bars represent mouse hearts perfused with Kreb
respectively. Values are mean±SEM of six hearts. Empty bars, hearts perfused with buffer
measurement of mouse hearts perfused with the buffer, or the Gpx1+/+ mouse hearts perfuwere ISOL-positive (Fig. 4). In contrast, there were 15±0.64% ISOL-
positive cardiomyocytes in DOX-treated mouse Gpx1−/− hearts.
3.4. Mouse hearts deﬁcient in Gpx1 display increased protein nitration
Protein nitration was investigated by the immunostaining of
3-nitrotyrosine (3-NT) in heart sections of DOX-treated Gpx1+/+ andnd wild type mice. Mouse hearts were perfused in vitro with Krebs–Henseleit buffer as
ry percentage after exposure to buffer or DOX compared to the basal levels measured in
s–Henseleit buffer only (as control) and Krebs–Henseleit buffer containing 5 µM DOX,
only; ﬁlled bars, hearts perfused with buffer containing DOX. a, Pb0.01 vs. the same
sed with DOX.
Fig. 1 (continued).
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throughout the heart sections. The immunostaining density of 3-NTwas
analyzed using a digital image system. The background of 3-NT staining
was negligible in both Gpx1+/+ and Gpx1−/− control mouse hearts (data
not shown). DOX caused elevated immunostaining of 3-NT in mouse
hearts; and the density was three-fold higher in Gpx1−/− hearts relative
to Gpx1+/+ hearts (Fig. 5B, C). Little stainingwas observed in the absence
of primary nitrotyrosine antibody (Fig. 5A).4. Discussion
Free radicals mediate DOX-induced cardiotoxicity. However, a
minimal set of studies have investigated the role of the antioxidant
enzyme Gpx1 in DOX-induced cardiotoxicity. We hypothesized that if
Gpx1 plays a critical role in preventing DOX-induced cardiotoxicity,
then mouse hearts overexpressing this enzymewill exhibit a resistant
phenotype. Conversely, we hypothesized that mouse hearts deﬁcient
Table 2
In vivo cardiac function of Gpx1+/+ and Gpx1−/− mice treated with or without DOX
Parameter Units Gpx1+/++
saline
Gpx1−/−+
saline
Gpx1+/++
DOX
Gpx1−/−+
DOX
Weight g 30.4±0.64a 28.9±1.71a 24.0±1.08b 23.2±0.48
HR beats/min 528±2a 526±12a 471±5a,b 388±24
CI μl/g 222±6a 226±16a 163±8a,b 106±9
SI μl/g 0.42±0.01a 0.43±0.02a 0.35±0.02a,b 0.28±0.02
EF % 71.4±0.56a 70.02±0.67a 51.2±1.01a,b 41.8±1.71
PRSW mmHg 91.1±2.92a 87.2±4.51a 62.2±2.96a,b 44.5±3.26
Systolic function
Pes mmHg 93.1±0.74a 92.9±0.29a 67.1±1.69a,b 60.5±2.68
Ves μl 5.10±0.13a 5.03±0.07a 7.83±0.26a,b 9.19±0.18
dP /dtmax mmHg/s 8093±226a 8132±379a 5566±111a,b 4406±331
dP /dtmax−Ved mmHg/μl 507±27a 533±42a 332±49b 263±19
Diastolic function
Ped mmHg 3.39±0.38a 3.17±0.45a 6.26±0.20b 6.13±0.76
Ved μl 17.82±0.15a 17.26±0.23a 16.02±0.25a,b 14.87±0.50
dP /dtmin mmHg/s 6932±165a 7028±590a 5599±142a,b 3504±336
τ(Weiss) ms 6.74±0.11a 5.95±0.25a 7.96±0.26a,b 10.26±0.64
β(beta) mmHg/μl 0.47±0.04 0.34±0.04 0.34±0.05 0.29±0.08
Vascular function
Ea mmHg/μl 7.14±0.09a 7.66±0.16a 7.76±0.34a 9.15±0.13
Gpx1+/+ or Gpx1−/− mice were injected with DOX (22.5 mg/kg, i.p.) or saline. Five days
later, in vivo cardiac function was measured by the Millar conductance catheter system
as described in Materials and methods. Values are mean±SEM of 6 mice.
HR, heart rate; Ved, end-diastolic volume; Ves, end-systolic volume; SI, stroke index
(SI=SV/body wt); EF, ejection fraction; CI, cardiac index; PRSW, preload recruitable
stroke work; Pes, end-systolic pressure; Ped, end-diastolic pressure; dP /dtmax (or min),
themaximal rate of pressure increasing (or decreasing); dP /dtmax−Ved, slope describing
isovolumic contraction; τWeiss, the mono-exponential time constant of relaxation;
β, slope of end-diastolic pressure–volume relationship; Ea, arterial elastance.
a Pb0.05 vs. Gpx1−/−+DOX.
b Pb0.05, Gpx1+/++DOX vs. Gpx1+/++saline.
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demonstrated that overexpression of Gpx1 in the heart attenuated
cardiac dysfunction and improved mitochondrial complex respiration
activity [21]. Our current study demonstrates that Gpx1 deﬁciency
dramatically exacerbates DOX-induced in vivo cardiac dysfunction.
We also show that DOX-induced impairment in mitochondrial
respiratory activity was more profound in mice lacking Gpx1. It may
be possible that impaired mitochondrial activity leads to increased
H2O2, increased protein nitration, and ultimately cardiomyocyte
apoptosis.
Our in vitro studies demonstrated that Gpx1 partially reversed the
DOX-induced deﬁcits, including impaired contractility and diastolic
function, decreased coronary ﬂow rate, and reduced HR (Fig. 1). The
toxic effects of DOX have been observed on perfused rat hearts in
other studies [26,27]. Although the mechanism responsible for these
alterations of cardiac function is uncertain, it has been previously
shown that OH· formation inDOX-perfused rat hearts is involved in the
toxic response [7]. Free radicals are known to have a detrimental effect
on endogenous vascular regulators, such as nitric oxide (NO), a strong
vascular dilator. Coronary vascular constriction or endothelial damage
could play a role as well. Pelikan et al. have found that DOX elevates
coronary resistance in DOX-perfused rat heart [27], whichmay explain
why the coronary ﬂow decreased in DOX-perfused Gpx1−/− mouse
hearts but not in wild type mouse hearts in our study. It is likely that
the cardioprotective effects of Gpx1 can be primarily attributed to its
antioxidant activity. However, it should be noted that heart rate was
signiﬁcantly decreased following exposure to DOX in our in vitro
cardiac function study, which was done in the absence of pacing.
Reduction of heart rate likely has a negative impact on cardiac function
and contractility due to underperfusion of cardiac muscle. The exact
mechanism of DOX cardiotoxicity would ideally be explored in an
isolated and pacedworkingheart, although todate, this has never been
technically achieved in mouse hearts.
Our in vivo cardiac function study shows that DOX signiﬁcantly
decreased CO, EF, and PRSW, indicatingheart failure in thesemice. DOX
treatment induced both systolic and diastolic dysfunction, which was
magniﬁed in Gpx1−/− mice. DOX-induced decrease in dP /dtmax−Ved
suggests an effect on the calcium cycling proteins during isovolumic
contraction, while DOX-induced decrease in τ suggests an effect on
SERCA2a and/or phospholamban during isovolumic relaxation. An
increase in Ea suggests that arterial vascular resistance is affected by
DOX in Gpx1−/− mice. There was no change in β in DOX-treated mice,
suggesting that there is no effect on the cardiac extracellular matrix
during the passive ﬁlling phase.
Mitochondria are the major intracellular ATP generation sites;
their swelling and destruction in human and animal hearts
following exposure to DOX are well documented in many studies
[28,29]. To further explore the possible role of Gpx1 in
mitochondrial damage, we assessed mitochondrial respiration
function from DOX- or saline-treated mouse hearts. Our studies
showed that DOX treatment signiﬁcantly compromises the
efﬁciency of mitochondrial respiration in hearts of both wild
type and Gpx1 knockout mice. However, the functional decline of
cardiac mitochondria in knockout mice was signiﬁcantly more
severe, suggesting that Gpx1 mediates mitochondrial protection
subsequent to DOX-induced damage.
The effect of DOX on cardiac mitochondrial respiration has
been previously reported in a number of studies. The size of
the effect varies according to differences in the dosage of DOX
treatment, the genetic background of the mice, and the species
(mice vs. rats) used in the studies [30–34]. In our study, DOX at
22.5 mg/kg had no effect on NAD- or FAD-linked state 3
respiration in mitochondria of either wild type or Gpx1 knockout
mice, suggesting that DOX does not affect the rate of ATP
synthesis. Nonetheless, DOX treatment caused a more profound
uncoupling of oxidative phosphorylation from the electrontransport chain in NAD-linked respiration in mitochondria of
Gpx1-deﬁcient hearts compared to those of normal hearts, as
suggested by the decreased P/O ratios of these samples. The
uncoupling was also observed in FAD-linked respiration in
mitochondria of Gpx1-deﬁcient hearts but not wild type hearts.
Finally, it should be noted that the rate of NAD-linked state 4
respiration was signiﬁcantly increased upon DOX administration
in cardiac mitochondria of Gpx1 knockout mice, but not wild type
mice. This increased state 4 respiratory rate suggests that
mitochondria cannot maintain a proper chemiosmotic gradient,
possibly because DOX treatment signiﬁcantly damages the
mitochondrial inner membrane. On the other hand, FAD-linked
state 4 respiration was not affected in Gpx1-deﬁcient cardiac
mitochondria, indicating that the DOX-induced increase in the
rate of state 4 respiration is substrate-speciﬁc. The mechanisms
by which substrates affect state 4 respiration remain to be
determined.
In our study, we showed increased protein nitration in Gpx1-
deﬁcient mice, suggesting that DOX-induced ROS exert their deleter-
ious effects partly by increasing protein nitration. Previous studies
have shown that DOX treatment of the heart raises nitric oxide levels
by increasing iNOS expression [35]. NO and superoxide anion react to
generate peroxynitrite, a potent oxidant that partially mediates DOX-
induced cardiotoxicity by causing nitrosative stress on proteins, lipids,
and nucleic acids [36]. Mitochondria are particularly sensitive targets
for peroxynitrite-induced toxicity, which may lead to their impaired
function resulting in further production of superoxide and H202.
Pacher et al. established a pivotal role of peroxynitrite in DOX-induced
cardiac dysfunction by demonstrating that FP-15, a peroxynitrite
decomposition catalyst, protected against protein nitration and
cardiac dysfunction [37]. Furthermore, both H202 and peroxynitrite
can induce DNA damage and lead to the overactivation of the nuclear
Fig. 2. Gpx1-deﬁcient mouse hearts are more susceptible to DOX-induced declines in NAD-linked electron transfer and energy coupling capacities in mitochondria. (A) DOX
treatment had no effect on NAD-linked state 3 respiration in cardiac mitochondria of either wild type or Gpx1 knockout mice. (B) However, the same treatment caused an increase
in the rate of state 4 respiration in cardiac mitochondria of Gpx1 knockout mice, but not wild type mice. a, pb0.001 vs. saline-treated Gpx1 knockout mice and saline- or DOX-
treated wild type mice. The efﬁciency of NAD-linked oxidative phosphorylation in cardiac mitochondria, as determined by RCI (C) and P/O ratio (D), was more severely affected in
by DOX treatment in Gpx1 knockout mice than inwild type mice. In (C), b indicates pb0.001 vs. saline-treated wild type mice. In (D), c indicates pb0.01 vs. saline-treated wild type
mice. In (C) and (D), a indicates pb0.001 vs. saline-treated Gpx1 knockout and saline- or DOX-treated wild type mice. Values are mean±SEM for all ﬁgures. N≥4 mice for each
experiment.
Fig. 3. Effect of Gpx1 deﬁciency on FAD-linked electron transfer and energy coupling capacities in cardiac mitochondria of wild type and Gpx1 knockout mice in response to DOX
treatment. Gpx1 deﬁciency had no effect on FAD-linked state 3 respiration (A), state 4 respiration (B), and RCI (C) of cardiac mitochondria from either wild type or Gpx1 knockout
mice. The P/O ratio of cardiac mitochondria from Gpx1 knockout mice, but not wild type mice, decreased after DOX treatment (D). In (D), a indicates pb0.001 vs. saline-treated Gpx1
knockout and saline- or DOX-treated wild type mice. Values are mean±SEM for all ﬁgures. N≥4 mice for each experiment.
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toxicity [38].
DOX-induced reactive oxygen species and reactive nitrogen species
also activate matrix metalloproteinases, such as MMP-2 and MMP-9
[39,40]. These matrix degrading enzymes have been associated with
cardiac failure. Whether DOX treatment leads to higher MMP-2 or
MMP-9 levels in Gpx1−/− mouse hearts warrants further investigation.
Several groups have reported that cardiomyocyte apoptosis is in-
volved in cardiac injury inducedbyanthracycline antibiotics [4,5,41–43].
Peroxynitrite has been found to cause apoptosis in cardiomyocytes [44].
As shown in Fig. 4, Gpx1 hearts displayed a signiﬁcant increase in ISOL-
positive apoptosis. These results support a recent study that showed that
oxidative stress is involved inDOX-induced apoptosis and that this stress
can be inhibited by Gpx1.
In summary, our study demonstrates that Gpx1 deﬁciency renders
hearts more susceptible to DOX-induced cardiotoxicity. This cardio-
toxic effect involves mitochondrial dysfunction, an increase in
apoptosis, and an increase in protein nitration. These ﬁndings suggest
a therapeutic role for agents such as probucol [18] and melatoninFig. 4. Effect of DOX on apoptosis in hearts from Gpx1−/− mice. ISOL procedure was perform
Representative staining pattern of hearts from Gpx1+/+ (A), DOX+Gpx1+/+ (B), Gpx1−/− (C), an
nuclei of myocytes were determined by random counting of 10 ﬁelds per section. Each bar
Pb0.05, DOX+Gpx1−/− mice vs. DOX+Gpx1+/+ mice.[45,46], both of which increase Gpx1 activity in the heart. This
possibility warrants further study.
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